SuperGen ceo joins BIO board

James Manuso joins the US-based biotechnology organisation

James Manuso, chief executive of SuperGen, a US developer of novel cancer therapies, has been elected to the board of the Biotechnology Industry Organization (BIO), based in Washington, DC.

BIO’s board includes members of the governing boards for each of the organisation’s four sections: health, emerging companies, industrial and environmental and food and agriculture. Manuso has joined BIO’s health section governing board.

In addition, Manuso will serve on the BIO board Standing Committee on International Affairs.

SuperGen has been a member of BIO since 2003.

Manuso has been SuperGen chairman, president and chief executive since January 2004. He is co-founder and immediate past president and chief executive of Galenica Pharmaceuticals.

The Biotechnology Industry Organization (BIO) represents more than 1,100 biotechnology companies, academic institutions, biotechnology centres and related organisations across the US and in more than 30 other nations.

BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.

You may also like

Finance

SuperGen to acquire Astex Therapeutics

Creating an international developer of cancer drugs
Pharmaceutical

AIRPLAN S.A. showcases its dual strength in engineering and technology at CPHI 2025

AIRPLAN S.A. will once again participate in CPHI 2025, the world’s premier pharmaceutical event, taking place from October 28 to 30 in Frankfurt (Hall 9.0, booth B29)
Pharmaceutical

NEXTEN: Tomorrow's Tableting Innovations

A world première of the new IMA Active tablet presses
Pharmaceutical

Global vaccine patents up 7% in a year despite US government's stance

Vaccine patent applications show sustained momentum after the COVID pandemic, with RNA vaccines now dominating the filings
Manufacturing

Rezon Bio launches as European biologics CDMO with mirrored sites in Poland

New CDMO combines cost efficiency, digital innovation and EMA/FDA-audited facilities in Gdańsk and Warsaw to accelerate biologics development and commercialisation
Manufacturing

Baxter earns first Gold Resiliency Badge from HIRC across IV, nutrition and premix drug categories

The company is the first manufacturer to receive the Healthcare Industry Resilience Collaborative’s gold badge for IV solutions, nutrition solutions and premix drugs, recognising its leadership in building a transparent, reliable and disruption-ready healthcare supply chain
You need to be a subscriber to read this article.
Click here to find out more.
Analysis

From West to East: building biotech bridges across APAC and the Middle East

Amid rising geopolitical uncertainty, US biotech companies are looking beyond tariffs and trade tensions to expand into Asia-Pacific and the Middle East
Subscribe now